Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 25, 2011

View Archived Issues

Lundbeck profiles pipeline progress of third quarter 2011

Preclinical and clinical results reported for Myrexis oncolytic compounds

Melphalan flufenamide evaluated in phase I/IIa study

New anticoagulants show promise in proof-of-concept studies in vivo

Favorable preclinical results reported for Shionogi's new anti-atherosclerotic agent

Phase III study investigates phosphate-lowering effects of SBR-759

Multicomponent natural medication may target multiple Alzheimer's disease pathways

Phase II trial of Zaleplon Accordion Pill shows promise in insomnia

Additional dosage and indication approved for Herceptin in Japan

Daiichi Sankyo and Provepharm enter license agreement for methylthioninium chloride in Japan

Genfit reports encouraging preclinical data for GFT-505 in NAFLD/NASH

Kinentia Biosciences prepares new mu opioid receptor ligands

Mitsubishi Tanabe Pharma set to launch Imusera in Japan for MS

Asahi Kasei Pharma launches Teribone in Japan

Novel IBAT inhibitors disclosed by GlaxoSmithKline

Researchers at Deciphera Pharmaceuticals present novel tyrosine-protein kinase inhibitors

Mitsubishi Tanabe Pharma prepares Japanese launch of Telavic

Novartis submits application for NVA-237 in Japan

New CYP17 inhibitors for cancer disclosed by Bristol-Myers Squibb

Biotest announces completion of phase IIa trial of tregalizumab

U.S. university team prepares new ether-based compounds

Respivert begins phase II study of RV-568

Additional indication for Modiodal approved in Japan

Iressa approved in Japan in new lung cancer indication